Literature DB >> 3540097

The treatment of refractory ascites by the LeVeen shunt. A multi-centre controlled trial (57 patients).

P Bories, D Garcia Compean, H Michel, M Bourel, J P Capron, A Gauthier, J Lafon, V G Lévy, J P Pascal, A Quinton.   

Abstract

A multi-centre random trial of 57 cases of alcoholic cirrhosis with refractory ascites was carried out; 29 patients received a LeVeen shunt and 28 were treated by conventional medical therapy. The effectiveness of the LeVeen shunt in reducing ascites was good in the first month, but was not different from conventional medical therapy by the end of one year. Complications were significantly more frequent in the surgical group. Of the 29 patients fitted with a LeVeen shunt, 25 developed one or more complications. Of the 28 patients in the medical control group, only 8 developed complications. The mortality rate of the two groups also differed significantly. Twelve patients in the surgical group (41%) died in the course of the first month against only 5 (18%) in the medical control group. By the end of one year, the mortality rate of the two groups was almost identical: 23 (79%) and 21 (75%) respectively. These observations confirm the poor prognosis for refractory ascites in cases of alcoholic cirrhosis and the inadvisability of attempting to treat it by implanting a LeVeen shunt.

Entities:  

Mesh:

Year:  1986        PMID: 3540097     DOI: 10.1016/s0168-8278(86)80028-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

Review 1.  Transjugular portosystemic stent shunt in treatment of liver diseases.

Authors:  M Schepke; T Sauerbruch
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

3.  TIPS for refractory ascites: a single-centre experience.

Authors:  Ulrich Thalheimer; Gioacchino Leandro; Dimitrios N Samonakis; Christos K Triantos; Marco Senzolo; Konrad Fung; Neil Davies; David Patch; Andrew K Burroughs
Journal:  J Gastroenterol       Date:  2009-07-02       Impact factor: 7.527

4.  The significance of the furosemide test for predicting ascites control by diuretics in cirrhotics: a comparison with volume expansion and octreotide infusion.

Authors:  Pierluigi Toniutto; Mario Pirisi; Carlo Fabris; Luca Apollonio; Kalliopi Sereti; Ettore G Bartoli
Journal:  Dig Dis Sci       Date:  2006-10-20       Impact factor: 3.199

5.  Concentrated ascitic fluid reinfusion after cascade filtration in tense ascites.

Authors:  L Rossaro; A Graziotto; S Bonato; M Plebani; D H van Thiel; A Burlina; R Naccarato; M Salvagnini
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

Review 6.  Role of surgical therapy in management of intractable ascites.

Authors:  J Elcheroth; C Vons; D Franco
Journal:  World J Surg       Date:  1994 Mar-Apr       Impact factor: 3.352

7.  TIPS for management of refractory ascites: response and survival are both unpredictable.

Authors:  Paul J Thuluvath; Jasdeep S Bal; Sally Mitchell; Gunnar Lund; Anthony Venbrux
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

Review 8.  Transjugular Intrahepatic Portosystemic Shunt Placement for Refractory Ascites: Review and Update of the Literature.

Authors:  Ana Cecilia Burgos; Bartley Thornburg
Journal:  Semin Intervent Radiol       Date:  2018-08-06       Impact factor: 1.513

9.  Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Amine Benmassaoud; Suzanne C Freeman; Davide Roccarina; Maria Corina Plaz Torres; Alex J Sutton; Nicola J Cooper; Laura Iogna Prat; Maxine Cowlin; Elisabeth Jane Milne; Neil Hawkins; Brian R Davidson; Chavdar S Pavlov; Douglas Thorburn; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2020-01-16

Review 10.  Evaluation and management of patients with refractory ascites.

Authors:  Bahaa Eldeen Senousy; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.